Australia is currently observing the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist , representing a significant advance in obesity treatment . Early clinical trials have demonstrated https://giant-liv-bike359609.wiki-jp.com/2686902/emerging_medication_in_australia_a_promising_breakthrough_for_weight_loss